Summary of Use during Lactation

Information in this record refers to the use of nitrogen-13 radiopharmaceuticals as diagnostic agents. International guidelines state that breastfeeding need not be interrupted after administration of radiopharmaceuticals containing nitrogen-13.[1,2]

Drug Levels

Nitrogen N 13 decays by positron emission, emitting gamma photon with an energy of 511 keV. It has a physical half-life of 9.96 minutes.[2]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP 2015;44 (2 Suppl):7-321. [PubMed: 26069086]

2.

Dilsizian V, Metter D, Palestro C, Zanzonico P. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Material. Final report submitted: January 31, 2019. 2019. https://www​.nrc.gov/docs​/ML1903/ML19038A498.pdf

Substance Name

Nitrogen-13

CAS Registry Number

13981-22-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Nitrogen Radioisotopes

Diagnostic Agents